|
14 Companies |
|
26 Products |
|
26 Products |
|
42 Mechanisms of Action |
|
0 Trials |
|
67 News |
|
| 12» |
- | temozolomide / Generic mfg., plerixafor / Generic mfg.
Trial completion, Trial completion date: Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma (clinicaltrials.gov) - Oct 23, 2018
P1/2, N=30, Completed, Sponsor: Lawrence Recht
Active, not recruiting --> Completed | Trial completion date: Nov 2022 --> Sep 2018
- | temozolomide / Generic mfg., plerixafor / Generic mfg.
Trial primary completion date: Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma (clinicaltrials.gov) - Jul 3, 2018
P1/2, N=30, Active, not recruiting, Sponsor: Lawrence Recht
Active, not recruiting --> Completed | Trial completion date: Nov 2022 --> Sep 2018 Trial primary completion date: Jul 2017 --> Nov 2017
- | Torisel (temsirolimus) / Pfizer
Phase classification, Metastases: A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors (clinicaltrials.gov) - Apr 17, 2018
P1, N=12, Completed, Sponsor: City of Hope Medical Center
Trial primary completion date: Jul 2017 --> Nov 2017 Phase classification: P=N/A --> P1
- | NN1213 / Novo Nordisk
Trial completion: Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors (clinicaltrials.gov) - Aug 23, 2017
P2, N=40, Completed, Sponsor: Burzynski Research Institute
Phase classification: P=N/A --> P1 Recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Antineoplaston Therapy in Treating Patients With Brain Tumors (clinicaltrials.gov) - Aug 22, 2017
P2, N=40, Completed, Sponsor: Burzynski Research Institute
Recruiting --> Completed Recruiting --> Completed
- | plerixafor / Generic mfg.
Enrollment closed, Trial initiation date: Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma (clinicaltrials.gov) - Jul 28, 2017
P1/2, N=30, Active, not recruiting, Sponsor: Stanford University
Recruiting --> Completed Recruiting --> Active, not recruiting | Initiation date: Jul 2014 --> Nov 2014
- | Enrollment change, Trial withdrawal, Trial primary completion date: Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors (clinicaltrials.gov) - Apr 28, 2017
P=N/A, N=0, Withdrawn, Sponsor: Sue O'Dorisio
Recruiting --> Active, not recruiting | Initiation date: Jul 2014 --> Nov 2014 N=30 --> 0 | Suspended --> Withdrawn | Trial primary completion date: Dec 2018 --> Mar 2017
- trebananib (AMG 386) / Amgen
Trial completion, Enrollment change, Trial primary completion date: Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors (clinicaltrials.gov) - Oct 3, 2016
P1, N=37, Completed, Sponsor: National Cancer Institute (NCI)
N=30 --> 0 | Suspended --> Withdrawn | Trial primary completion date: Dec 2018 --> Mar 2017 Active, not recruiting --> Completed | N=80 --> 37 | Trial primary completion date: Oct 2016 --> Apr 2016
- Trial primary completion date: Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors (clinicaltrials.gov) - Sep 8, 2016
P=N/A, N=30, Suspended, Sponsor: O'Dorisio, M S
Active, not recruiting --> Completed | N=80 --> 37 | Trial primary completion date: Oct 2016 --> Apr 2016 Trial primary completion date: Jul 2016 --> Dec 2018
- Trial primary completion date: Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors (clinicaltrials.gov) - Jun 21, 2016
P=N/A, N=30, Suspended, Sponsor: O'Dorisio, M S
Trial primary completion date: Jul 2016 --> Dec 2018 Trial primary completion date: Jul 2015 --> Jul 2016
- trebananib (AMG 386) / Amgen
Trial primary completion date: Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors (clinicaltrials.gov) - Mar 29, 2016
P1, N=80, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2015 --> Jul 2016 Trial primary completion date: Mar 2016 --> Oct 2016
- Recentin (cediranib) / AstraZeneca
Trial completion, Trial primary completion date: AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors (clinicaltrials.gov) - Mar 7, 2016
P1, N=55, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2016 --> Oct 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2012 --> Jul 2015
- melphalan / Generic mfg.
Trial termination: Melphalan With BBBD in Treating Patients With Brain Malignancies (clinicaltrials.gov) - Feb 17, 2016
P1, N=21, Terminated, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Completed | Trial primary completion date: Jan 2012 --> Jul 2015 Suspended --> Terminated; Other competing clinical trials affecting enrollment
- Trial completion, Enrollment change, Trial primary completion date: Study of Tissue Samples From Patients With Glioma or Other Brain Tumors (clinicaltrials.gov) - Nov 24, 2015
P=N/A, N=180, Completed, Sponsor: University Hospital, Montpellier
Suspended --> Terminated; Other competing clinical trials affecting enrollment Recruiting --> Completed | N=150 --> 180 | Trial primary completion date: Dec 2008 --> Jul 2009
- RG4733 / Roche
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - Sep 29, 2015
P1, N=22, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=150 --> 180 | Trial primary completion date: Dec 2008 --> Jul 2009 Active, not recruiting --> Completed | N=34 --> 22 | Trial primary completion date: May 2017 --> Jun 2013
- trebananib (AMG 386) / Amgen
Trial primary completion date: Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors (clinicaltrials.gov) - Sep 24, 2015
P1, N=80, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=34 --> 22 | Trial primary completion date: May 2017 --> Jun 2013 Trial primary completion date: Oct 2015 --> Mar 2016
- Trial primary completion date: Yoga Therapy in Treating Patients With Malignant Brain Tumors (clinicaltrials.gov) - Aug 13, 2015
P=N/A, N=9, Terminated, Sponsor: Comprehensive Cancer Center of Wake Forest University
Trial primary completion date: Oct 2015 --> Mar 2016 Trial primary completion date: Dec 2013 --> Sep 2012
- | emvododstat (PTC299) / PTC Therap
Trial completion, Trial primary completion date: PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors (clinicaltrials.gov) - May 4, 2015
P1, N=28, Completed, Sponsor: Pediatric Brain Tumor Consortium
Trial primary completion date: Dec 2013 --> Sep 2012 Suspended --> Completed | Trial primary completion date: May 2012 --> Jan 2015
- Trial suspension: Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors (clinicaltrials.gov) - Apr 22, 2015
P=N/A, N=30, Suspended, Sponsor: University of Iowa
Suspended --> Completed | Trial primary completion date: May 2012 --> Jan 2015 Recruiting --> Suspended
- melphalan / Generic mfg.
Trial primary completion date: Melphalan With BBBD in Treating Patients With Brain Malignancies (clinicaltrials.gov) - Apr 14, 2015
P1, N=20, Suspended, Sponsor: OHSU Knight Cancer Institute
Recruiting --> Suspended Trial primary completion date: Dec 2013 --> Dec 2015
- trebananib (AMG 386) / Amgen
Trial primary completion date: Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors (clinicaltrials.gov) - Mar 11, 2015
P1, N=80, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2013 --> Dec 2015 Trial primary completion date: Apr 2015 --> Oct 2015
- ||| Trial completion, Enrollment change, Trial primary completion date, MRI: Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging (clinicaltrials.gov) - Feb 5, 2015
P=N/A, N=80, Completed, Sponsor: Charite University, Berlin, Germany
Trial primary completion date: Apr 2015 --> Oct 2015 Recruiting --> Completed | N=100 --> 80 | Trial primary completion date: May 2015 --> Dec 2014
- Trial primary completion date: Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors (clinicaltrials.gov) - Oct 15, 2014
P=N/A, N=30, Recruiting, Sponsor: University of Iowa
Recruiting --> Completed | N=100 --> 80 | Trial primary completion date: May 2015 --> Dec 2014 Trial primary completion date: Jul 2014 --> Jul 2015
- temozolomide / Generic mfg.
Trial completion: Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors (clinicaltrials.gov) - Sep 30, 2014
P=N/A, N=16, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
Trial primary completion date: Jul 2014 --> Jul 2015 Active, not recruiting --> Completed
- Enrollment change: Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment (clinicaltrials.gov) - Aug 8, 2014
P1, N=0, Withdrawn, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed N=36 --> 0
- RG4733 / Roche
Trial primary completion date, Combination therapy: RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - Jul 30, 2014
P1, N=34, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=36 --> 0 Trial primary completion date: Jul 2014 --> May 2017
- plerixafor / Generic mfg.
Enrollment open: Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma (clinicaltrials.gov) - Jul 23, 2014
P1/2, N=29, Recruiting, Sponsor: Stanford University
Trial primary completion date: Jul 2014 --> May 2017 Not yet recruiting --> Recruiting
- Clinical: Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors (clinicaltrials.gov) - Jul 18, 2014
P=N/A, N=30, Recruiting, Sponsor: University of Iowa
- plerixafor / Generic mfg.
Trial primary completion date: Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma (clinicaltrials.gov) - Jul 10, 2014
P1/2, N=29, Not yet recruiting, Sponsor: Stanford University
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2016 --> Jul 2017
- plerixafor / Generic mfg.
Trial initiation date, Trial primary completion date: Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma (clinicaltrials.gov) - Jul 10, 2014
P1/2, N=29, Not yet recruiting, Sponsor: Stanford University
Trial primary completion date: Nov 2016 --> Jul 2017 Initiation date: Nov 2013 --> Jul 2014 | Trial primary completion date: Nov 2016 --> Jul 2017
- veliparib (ABT-888) / AbbVie
Trial completion, PARP Biomarker: ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors (clinicaltrials.gov) - Jun 19, 2014
P1, N=31, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: Nov 2013 --> Jul 2014 | Trial primary completion date: Nov 2016 --> Jul 2017 Active, not recruiting --> Completed
- RG4733 / Roche
Enrollment change, Combination therapy: RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - May 29, 2014
P1, N=24, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=34 --> 24
- veliparib (ABT-888) / AbbVie
Enrollment change, PARP Biomarker: ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors (clinicaltrials.gov) - Apr 20, 2014
P1, N=31, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=34 --> 24 N=24 --> 31
- | lenalidomide / Generic mfg.
Trial completion: Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=45, Completed, Sponsor: National Cancer Institute (NCI)
N=24 --> 31 Active, not recruiting --> Completed
- | Cilcane (cilengitide) / Iceni Pharma
Trial completion: Cilengitide in Treating Children With Refractory Primary Brain Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=24, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | temozolomide / Generic mfg.
Trial completion: Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=72, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | thalidomide / Generic mfg., docetaxel / Generic mfg.
Trial completion, Metastases: Thalidomide and Docetaxel in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Feb 22, 2014
P1, N=26, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | carboplatin / Generic mfg., temozolomide / Generic mfg., thiotepa / Generic mfg.
Trial completion, Combination therapy, Minimal residual disease: Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer (clinicaltrials.gov) - Feb 22, 2014
P1, N=0, Completed, Sponsor: New York University School of Medicine
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | paclitaxel / Generic mfg.
Trial completion, Metastases: Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas (clinicaltrials.gov) - Feb 19, 2014
P1, N=70, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed No longer recruiting --> Completed
- Rytelo (imetelstat) / Geron
Enrollment change: Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma (clinicaltrials.gov) - Jan 28, 2014
P1, N=34, Completed, Sponsor: Children's Oncology Group
No longer recruiting --> Completed N=45 --> 34
- | Rytelo (imetelstat) / Geron
Trial completion: Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma (clinicaltrials.gov) - Jan 28, 2014
P1, N=34, Completed, Sponsor: Children's Oncology Group
N=45 --> 34 Active, not recruiting --> Completed
- trebananib (AMG 386) / Amgen
Enrollment closed: Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors (clinicaltrials.gov) - Jan 14, 2014
P1, N=80, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- carboplatin / Generic mfg.
Trial completion, Metastases: Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 17, 2013
P1, N=0, Completed, Sponsor: University of Pittsburgh
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial initiation date, MRI: Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging (clinicaltrials.gov) - Nov 10, 2013
P=N/A, N=100, Recruiting, Sponsor: Charite University, Berlin, Germany
Active, not recruiting --> Completed Initiation date: May 2013 --> Nov 2013
- Enrollment open, MRI: Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging (clinicaltrials.gov) - Nov 10, 2013
P=N/A, N=100, Recruiting, Sponsor: Charite University, Berlin, Germany
Initiation date: May 2013 --> Nov 2013 Not yet recruiting --> Recruiting
- plerixafor / Generic mfg.
New P1/2 trial: Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma (clinicaltrials.gov) - Nov 5, 2013
P1/2, N=29, Not yet recruiting, Sponsor: Stanford University
- melphalan / Generic mfg.
Trial suspension: Melphalan With BBBD in Treating Patients With Brain Malignancies (clinicaltrials.gov) - Oct 24, 2013
P1, N=20, Suspended, Sponsor: OHSU Knight Cancer Institute
Not yet recruiting --> Recruiting Active, not recruiting --> Suspended
- Zolinza (vorinostat) / Merck (MSD)
Trial completion: Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma (clinicaltrials.gov) - Jun 30, 2013
P1, N=20, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Suspended Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial termination: MT2004-30: Tomotherapy for Solid Tumors (clinicaltrials.gov) - Jun 10, 2013
P1, N=23, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Replaced by another study
- Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change: MT2004-30: Tomotherapy for Solid Tumors (clinicaltrials.gov) - Jun 10, 2013
P1, N=23, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Terminated; Replaced by another study N=45 --> 23